Scribe projected to enter the clinic in mid-2026 with STX-1150, a PCSK9-targeting CRISPR epigenetic silencing therapy for durable LDL-C reduction ...
Researching are throwing lots of ideas at the wall to see what sticks, but the U.S. just put some serious cash behind the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback